RESPIRATORY SLEEP ALLERGY & CARDIAC
p 3188 0211
Currently Recruiting Trials
Idiopathic Pulmonary Fibrosis Intravenous infusion study
Familial Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
AbbVie-sponsored Phase 2a clinical trial investigating new intravenous treatment for Idiopathic Pulmonary Fibrosis (IPF) over 52 weeks with an optional open lable extension study.
Who may be suitable?
- Individuals >40 years of age
- History of IPF diagnosis within 7 years
- Either stable treatment with antifibrotics for at least 8 weeks prior to the first visit or not treated with antifibrotics for at least 4 weeks prior to the first visit
A double blind, randomised, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis to reduce the risk of worsening (DROP-FPF)
Who may be suitable?
- Individuals >40 years of age
- Participants must have at least 1 first-degree relative (biological parent, sibling, or child) with confirmed pulmonary fibrosis
- No prior or current use of nerandomilast, nintedanib, or pirfenidone
Upcoming Recruiting Trials
Boehringer Ingelheim Fibroneer ACT 1305-0152
Intistitial Lung Disease
Participants with non-IPF fibrosing ILDs who do not fulfil the criteria for PPF, as assessed by the investigator, but are considered at clinical risk of developing PPF (e.g. due to specific ILD diagnoses, extensive fibrotic changes and/or presence of typical fibrotic patterns on chest HRCT).
Who may be suitable?
- Individuals >18 years of age
- <3 years since interstitial lung disease diagnosis
- Patients with non-IPF fibrosing interstitial lung diseases are eligible for treatment with nintedanib or nerandomilast after their disease has become progressive
Contineum Therapeutics CTX-791-201
Idiopathic Pulmonary Fibrosis
LRQ will be undertaking a clinical trial to investigate the efficacy of PIPE-791 at 1 mg daily and 3 mg daily compared to placebo based on the change in their breathing test from the start of the trial.
Who may be suitable?
- Individuals >40 years of age
- A diagnosis of IPF within the last 7 years
- Total body weight >40kg
Palm Progressive Pulmonary Fibrosis INS1009-331
Palm Idiopathic Pulmonary Fibrosis INS1009-321
Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel group Study of Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Progressive Pulmonary Fibrosis (PPF).
Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel group Study of Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Idiopathic Pulmonary Fibrosis (IPF).
Who may be suitable?
- Individuals >40 & <85
- A diagnosis of PPF within the last 7 years
Who may be suitable?
- Individuals >40 & <85
- A diagnosis of IPF within the last 7 years
Chiesi Fable
Bronchiectasis
A Phase III, Randomised, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Treatment With CHF10196 Tablets (Florensocatib) Compared With Placebo for up to 78 Weeks, Followed by an Open-label Extension, in Male and Female Participants 12 to 85 years of Age With Bronchiectasis.
Who may be suitable?
- >12 years, <85 years
-
Ongoing Active Studies
*Below studies are closed for recruitment
Boehringer Ingelheim 1305-0031
Idiopathic Pulmonary Fibrosis
This extension trial, 1305-0031, is aimed to assess the tolerability, long-term safety, and efficacy of nerandomilast (BI 1015550) in patients with IPF and PPF over a longer duration of treatment.
15 patients have been recruited onto the BI 31 study.
Sanofi AATD Inc.
INBRX-101 SAR447537
Alpha-1 Antitrypsin Deficiency
This is a Phase 2, multicenter, single-arm, open-label extension (OLE) study to evaluate the long-term safety and efficacy of SAR447537 in participants with alpha-1 antitrypsin deficiency (AATD) emphysema. 17 participants have been recruited for the INBRX.
United Therapeutics Corp. RIN-PF-302
Idiopathic Pulmonary Fibrosis/ Progressive Pulmonary Fibrosis
An Open-label Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease. The primary objective is to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with IPF or PPF. 8 participants have been recruited for the UT OLE study.
Boehringer Ingelheim AIRTIVITY 1397-0014
Bronchiectasis
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study). 10 participants have been recruited for the Airtivity study.
MIST AP01-007
Devpro PPF
Progressive Pulmonary Fibrosis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF). 2 participants have been recruited onto the Mist Devpro PPF study.
United Therapeutics Corp. RIN-PF-305
Progressive Pulmonary Fibrosis
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF). 2 patients have been recruited onto the UT RIN-PF-305 study.
Endeavor Biomedicines
WHISTLE-PF. ENV-IPF-103
Idiopathic Pulmonary Fibrosis
ENV-101 is an orally available Smoothened (Smo) inhibitor that blocks Hedgehog (Hh) pathway signaling. Patients will receive a dose of 50 mg, 100 mg or 200 mg of ENV-101, or PBO, once daily. 14 participants have been recruited onto the Whistle-PF study.
Syndax Pharmaceuticals
SNDX-6352-0506
Idiopathic Pulmonary Fibrosis
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)